[Federal Register Volume 72, Number 199 (Tuesday, October 16, 2007)]
[Notices]
[Page 58649]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-20372]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2007-0037]


Grant of Interim Extension of the Term of U.S. Patent No. 
4,971,802; MIFAMURTIDE

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued a 
certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension 
of the term of U.S. Patent No. 4,971,802.

FOR FURTHER INFORMATION CONTACT: Raul Tamayo by telephone at (571) 272-
7728; by mail marked to his attention and addressed to the Commissioner 
for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 
22313-1450; by fax marked to his attention at (571) 273-7728, or by e-
mail to [email protected].

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to a year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On August 8, 2007, IDM Pharma, agent/licensee of patent owner 
Novartis, timely filed an application under 35 U.S.C. 156(d)(5) for an 
interim extension of the term of U.S. Patent No. 4,971,802. Claims of 
the patent cover the product Mifamurtide having the active ingredient 
muramyl tripeptide phosphatidyl ethanolamine. The application 
indicates, and the Food and Drug Administration has confirmed, that a 
New Drug Application for the human drug product Mifamurtide has been 
filed and is currently undergoing regulatory review before the Food and 
Drug Administration for permission to market or use the product 
commercially.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review 
period will continue beyond the expiration date of the patent (November 
20, 2007), interim extension of the patent term under 35 U.S.C. 
156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 4,971,802 is granted for a period of one year from the 
expiration date of the patent, i.e., until November 20, 2008.

    Dated: October 4, 2007.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual Property and Director of 
the United States Patent and Trademark Office.
 [FR Doc. E7-20372 Filed 10-15-07; 8:45 am]
BILLING CODE 3510-16-P